卵巢上皮性癌患者血清TK1浓度的检测及临床意义

目的观察卵巢癌患者血清细胞质胸苷激酶（TK1）浓度的变化，初步探讨其临床意义。方法免疫印迹增强发光法检测30例卵巢良性上皮性肿瘤、75例卵巢上皮性癌、40名健康妇女血清TK1浓度。结果41．33％（31／75）宫颈癌患者患者血清TK1为阳性，平均浓度为（2．99±1．09）pM，显著高于卵巢良性肿瘤组或健康对照组（P〈0．05）；宫颈癌患者TK1浓度随临床分期的进展而增高，Ⅲ-Ⅳ患者的血清浓度出率高于I、Ⅱ期患者，差异有统计学意义（P〈0．05）；术后宫颈癌患者血清TK1浓度为（1．09±0．31）pM，与术前相比显著降低（P〈0．05）。结论血清TK1浓度对宫颈癌患者的诊断、预后及疗效的评价具有潜在的应用价值。

Study on patients with ovarian epithelial carcinoma and serum TK1 concentration detection and its clinical significance

Objective To study the concentration and clinical significance of Cytosolic Thymidine Kinase （TK1） in patients with ovarian cancer. Methods A chemiluminescent dot blot assay was employed to determine the serum concentration of TK1 in healthy women,patients with benign ovarian tumor, or epithelial ovarian carcinoma. Results The serum concentration of TK1 in patients with ovarian cancer was （2. 99 ± 1.09） pM which was significantly higher than that in patients with benign ovarian tumor or health donors（ P 〈 0. 05 ）. The serum concentration of TK1 in patients with epithelial ovarian careinoma increased with advance of the clinical stages. The concentration in III - IV patients was significant higher than that in I, II patients（P 〈 0. 05 ）. Furthermore, the serum concentration of TK1 in patients was significantly decreased to （ 1.09 ± 0. 31 ） pM after surgical resection. Conclusion There was potentially clinical application value of Cytosolic Thymidine Kinase for diagnosis, prognosis and evaluation or curative effecting for epithelial ovarian carcinoma.